It’s Optum, not Amazon, that is ‘scaring the crap' out of hospitals

For all the attention given to forays from Amazon, Apple and Walmart into the healthcare space, traditional providers are more worried about the continued expansion of UnitedHealthGroup’s Optum into clinical care, according to an article in Bloomberg.

Unlike the more recent moves by potential outside disruptors, Optum has been acquiring practices for nearly a decade. It now employs or is affiliated with 30,000 physicians and will add on another 17,000 as long as its $4.9 billion acquisition of DaVita Medical Group is completed as expected later this year—giving it a physician workforce beyond that of for-profit hospital giant HCA and any other medical group owner in the U.S.

“This is obviously scaring the crap out of hospitals in many markets,” said Chas Roades, CEO of consulting firm Gist Healthcare.

With that reach comes more power to keep patients away from higher-cost hospital stays as well as limiting care to UnitedHealth’s narrow networks. While the company won’t say which markets it operates in, confirm its roster of employed physicians or detail how many patients come from UnitedHealth insurance plans, it also said it has no plans to shut out other insurers.

“We have been slowly, steadily, methodically aligning and partnering with phenomenal medical groups who choose to join us,” said Andrew Hayek, who oversees the care delivery operation at UnitedHealth. “The shift towards value-based care and enabling medical groups to make that transition to value-based care is an important trend.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.